Devices, digital health, and the technology changing how care is delivered.
Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on discovery of assets across Takeda’s therapeutic areas of interest.
These three patterns keep showing up, and each is much cheaper to prevent than to fix later. The post Your Healthcare AI Strategy Is Probably an Architecture Problem appeared first on MedCity News .
When workers feel stuck in place, with limited opportunities to advance or deepen their skills, disengagement tends to follow. In allied health roles, where burnout is already high and many touch the patient experience, it is a risk healthcare employers cannot afford to ignore. The post Healthcare Retention Depends On Better Pathways, Not Just Better Pay appeared first on MedCity News .
These tools are worth implementing. They are not worth implementing without the right preparation. The post What Healthcare Leaders Should Know Before Implementing AI-Powered Documentation Tools appeared first on MedCity News .
Introduction Growing evidence suggests that higher ambient temperatures may increase the risk of mental health disorders and exacerbate existing conditions. Despite this, most studies evaluating the association between temperature and mental health rely on hospitalisation records or insurance claims data, which only capture the most severe outcomes. To effectively intervene to prevent mental health crises associated with ambient temperature, it is necessary to identify and develop novel ways to reach patients before they require care. Digital health tools offer a promising way to address these…
Pacira BioSciences offloaded its cold-therapy pain relief device to medtech orthopedics specialist Zimmer Biomet in a deal valued at up to $140 million.
Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates.
QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront, bagging a potentially symptom-relieving drug candidate that is on the cusp of phase 2.
Anthropic unveiled Claude Science, an AI workbench designed to run — not just assist with — pharma research. The company is seeking to build out its customer base in the pharma sector as it deepens its healthcare push ahead of a widely anticipated IPO. The post Anthropic Launches Claude Science to Court Pharma Ahead of IPO appeared first on MedCity News .
This cross-sectional study examines the association of race and ethnicity, health insurance type, and socioeconomic disadvantage with differences in continuous glucose monitoring among adults and children with diabetes.
Servier completed its acquisition of Day One Biopharmaceuticals and its buyout of Edgewise Therapeutics’ neuromuscular business is expected to close later this year. At the BIO International Convention, Servier’s top business development executive explained the rationale for these deals and how they fit the company’s overall strategy. The post Servier Executive: ‘We Are Not Looking for Blockbusters, We’re Looking for Innovative Science’ appeared first on MedCity News .
When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform the “greatest credible competitive threat in years.”
Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmaceuticals has pivoted away from its lead asset to structure its pipeline around two earlier-stage drug candidates.
In this month’s pivot podcast, I speak to the chief medical officer of San Francisco-based Vynca, an innovative company in the world of palliative care that is providing serious disease management at home. The post MedCity Pivot Podcast: The Evolution of Palliative Care at Home appeared first on MedCity News .
Pacira’s iovera device uses cold therapy for targeted pain relief. An analyst said the addition complements Zimmer Biomet’s portfolio.
Christina Zamarro will take over the role in July after spending nearly 20 years at Goodyear Tire & Rubber Company, most recently serving as its CFO.
This requires more than deploying the right technology. It demands a reevaluation of how these systems fit into the healthcare environment and how to bring patients and staff along. The post Hospitals Have Always Had Eyes — AI is Giving Them a Brain appeared first on MedCity News .
We should ask a more nuanced question than “does AI work in drug discovery.” Rather, we should ask which approaches are about to be proven, and which are about to be exposed, because the field is several bets, and they are not equally sound. The post The AI Drug Discovery Race Is Heating Up, Not In the Way You Think appeared first on MedCity News .
To meet the modern patient where they are, we must pivot away from managing chronic diseases to preventing them entirely, replacing a legacy system of triage with a new model that emphasizes proactive, personalized prevention. The post From Management to Personalized Prevention: The Phase Shift in Chronic Disease appeared first on MedCity News .
More than 40 million Americans live with migraine and other headache disorders. They include children trying to stay in school, workers trying to remain employed, parents caring for their families, veterans and first responders living with post-traumatic headache, and more. The post Headache Disorders Have Been Part of the American Story for 250 Years appeared first on MedCity News .
Vijay Kumar, the acting head of the FDA office that oversees new gene therapies, is stepping down from his role after a year in the job.
Abivax has recovered from a dent in its share price after unveiling fresh safety data that appeared to ease investors’ concerns with its ulcerative colitis prospect.
A sharp reduction in layoffs continued in the second quarter, extending a trend that started last fall.
U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.